Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 279 recruiting now early-phase tilt #6 of 28,963 conditions

Cancer: early-phase trial registry

279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #6 of 28,963 conditions by registered trial count.

621 US clinical trials · 279 currently recruiting · #6 of 28,963 conditions by registered trial count

Cancer: 621 US clinical trials tracked, 279 recruiting.

Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.

Open enrollment, early-phase tilt

Cancer has 621 registered US clinical trials, 279 of them open to new participants right now, about 45% of the total.

279
recruiting participants now
45%
of trials open to enrollment
31
in Phase 3-4 (later-stage)
31
top sponsor: M.D. Anderson Cancer Center

Corpus placement: #6 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer is recruiting above its size-band peers.

    279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cancer trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cancer enrolment sits around 108 participants.

    Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.

  4. Cancer research is mostly interventional.

    462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1116Phase 248Phase 327Phase 44

Open and recent trials

621 total, page 11 of 13

COMPLETED Phase 2 53 participants

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT00357084

COMPLETED Phase 4 52 participants

Tobacco Treatment Comparison for Cancer Care

University of Wisconsin, Madison

NCT06218823

COMPLETED 52 participants

Body Composition Post Cancer Treatment

Prisma Health-Upstate

NCT03690401

COMPLETED Phase 1 51 participants

Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors

University of Maryland, Baltimore

NCT05499663

COMPLETED 51 participants

Body Composition During Cancer Treatment

Prisma Health-Upstate

NCT03784911

COMPLETED NA 50 participants

Development of Calm for Cancer Prototype Mobile App

Calm.com

NCT05459168

COMPLETED Phase 1 50 participants

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Advaxis

NCT02325557

COMPLETED Phase 1 48 participants

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

CanBas Co.

NCT00551512

COMPLETED NA 47 participants

The Families Addressing Cancer Together Intervention for Parents With Cancer

UNC Lineberger Comprehensive Cancer Center

NCT05377749

COMPLETED NA 47 participants

eMOTION Formative Study

University of Southern California

NCT06125964

COMPLETED 47 participants

Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy

Connecticut Children's Medical Center

NCT04036032

COMPLETED Phase 1 45 participants

Phase I Study of TAS-106 in Combo With Carboplatin

M.D. Anderson Cancer Center

NCT00752011

COMPLETED NA 44 participants

The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older

UNC Lineberger Comprehensive Cancer Center

NCT02191982

COMPLETED 44 participants

Microbiome in Lung Cancer and Other Malignancies

Taher Abu Hejleh

NCT03688347

COMPLETED Phase 1 44 participants

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Esanex

NCT00506805

COMPLETED Phase 1 43 participants

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America

NCT02482168

COMPLETED NA 42 participants

VIDeOS for Smoking Cessation

Medical University of South Carolina

NCT06307496

COMPLETED Phase 1 42 participants

Oral Administration of STC-15 in Subjects With Advanced Malignancies

STORM Therapeutics

NCT05584111

COMPLETED Phase 1 41 participants

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Kadmon Corporation

NCT00086528

COMPLETED NA 40 participants

IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial

The University of Texas Medical Branch, Galveston

NCT01869348

COMPLETED Phase 1 40 participants

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

R-Pharm

NCT00422097

COMPLETED NA 40 participants

STEP AND GO: A Study of Technology-based Exercise Promotion

The University of Texas Medical Branch, Galveston

NCT01953224

COMPLETED Phase 1 39 participants

Study of NK012 in Patients With Refractory Solid Tumors

Nippon Kayaku Co.

NCT00542958

COMPLETED 39 participants

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2

Mayo Clinic

NCT02018640

COMPLETED Phase 1 39 participants

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT00437372

COMPLETED Phase 2 39 participants

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

University of Pittsburgh

NCT00226239

COMPLETED Phase 2 38 participants

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Cephalon

NCT00236041

COMPLETED NA 38 participants

Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients

Duke University

NCT03459352

COMPLETED NA 38 participants

Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage

Roswell Park Cancer Institute

NCT01038024

COMPLETED NA 37 participants

Communicating About Sexual Concerns and Dysfunction Effectively (CASCADE) Program

Duke University

NCT03658161

COMPLETED Phase 1 37 participants

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Pfizer

NCT00927823

COMPLETED Phase 1 36 participants

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Novartis Pharmaceuticals

NCT00570284

COMPLETED Phase 1 36 participants

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Kartos Therapeutics

NCT02016729

COMPLETED NA 35 participants

Feasibility and Utilization of an Application-based Question Prompt List

Barbara Ann Karmanos Cancer Institute

NCT03676920

COMPLETED 35 participants

Human Tumor Sequencing Project

Scripps Translational Science Institute

NCT01608230

COMPLETED NA 34 participants

Tailored Home-Based Exercise Program for Multiple Chronic Conditions

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03874754

COMPLETED NA 33 participants

Supportive Care Delivered by Telemedicine to Cancer Patients at Home

Memorial Sloan Kettering Cancer Center

NCT04136340

COMPLETED NA 32 participants

SmartManage Stress Management for HIV+ Cancer Survivors

University of Miami

NCT04544917

COMPLETED Phase 1 32 participants

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

NCT00612703

COMPLETED Phase 1 31 participants

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Kadmon Corporation

NCT00336765

COMPLETED NA 31 participants

Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment

Cedars-Sinai Medical Center

NCT02360917

COMPLETED 30 participants

Lymphedema Sensor Technology Development Study

Northwestern University

NCT06778837

COMPLETED NA 30 participants

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

Massachusetts General Hospital

NCT02594696

COMPLETED Phase 2 30 participants

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

Fred Hutchinson Cancer Center

NCT00002673

COMPLETED Phase 1 30 participants

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Novartis Pharmaceuticals

NCT01691807

COMPLETED 30 participants

Improving Symptom Self-management in Adolescents & Young Adults With Cancer

Virginia Commonwealth University

NCT02974569

COMPLETED Phase 1 30 participants

A Trial of PDL192 in Subjects With Advanced Solid Tumors

Abbott

NCT00738764

COMPLETED 30 participants

Emotion Regulation and Cancer Caregiving

Stanford University

NCT06123416

COMPLETED Phase 1 30 participants

Vinorelbine and XR9576 to Treat Cancer

National Cancer Institute (NCI)

NCT00001944

COMPLETED Phase 1 30 participants

Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer

University of Alabama at Birmingham

NCT00581971

← Previous Page 11 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 116
Phase 2 48
Phase 3 27
Phase 4 4

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Cancer right now

279 recruiting of 621 indexed (45% open).

Phase mix: 31 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top sponsor: M.D. Anderson Cancer Center (31 trials), 9 others listed. 50 shown below, recruiting first. #6 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Cancer?

PlainTrial tracks 621 US clinical trials for Cancer, of which 279 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.